

# PRESS RELEASE



Stockholm May 19, 2017

## Wilson Therapeutics to present at Bioequity Europe

Jonas Hansson, Chief Executive Officer, will present Wilson Therapeutics at the 18<sup>th</sup> annual Bioequity Europe investor conference that will be held May 22-23, 2017 in Paris, France. The presentation will be held at 14:20 CET on May 23 at the conference venue Marriott Rive Gauche in Paris.

### About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics' lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit [www.wilsontherapeutics.com](http://www.wilsontherapeutics.com) for more information.

### For further information contact:

Jonas Hansson, CEO, Wilson Therapeutics AB

Telephone: +46 8 796 00 00

Email: [jonas.hansson@wtx.se](mailto:jonas.hansson@wtx.se)

Wilson Therapeutics AB (publ)

Org nr 556893-0357

Kungsgatan 3

SE-111 43 Stockholm